ACCEL Lite: The Expanding Biology of SGLT Biology; Receptor 2
Based on the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) and SCORED (Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk) trials, there is now evidence to treat patients with heart failure with preserved ejection fraction with sodium-glucose cotransporter-2 (SGLT2) inhibitors and to start treatment early in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction. In this interview, L. Kristin Newby, MD, MHS, FACC; Deepak L. Bhatt MD, FACC; and Shashank Sinha, MD, discuss the expanding biology of SGLT2.
Keywords: ACCELLite, Heart Failure, Metabolic Syndrome X, Primary Prevention, Sodium-Glucose Transporter 2, Diabetes Mellitus, Type 2, Stroke Volume, Cardiovascular Diseases, Risk Factors, Glycosides, Ventricular Dysfunction, Left, Renal Insufficiency
< Back to Listings